Erasca (ERAS) Competitors $1.55 +0.07 (+4.73%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.23%) As of 03/27/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. WVE, IMCR, ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, and OCULShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Wave Life Sciences (WVE), Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Wave Life Sciences Immunocore ANI Pharmaceuticals Dyne Therapeutics Indivior Amphastar Pharmaceuticals Ardelyx Evotec 89bio Ocular Therapeutix Wave Life Sciences (NASDAQ:WVE) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Which has better valuation & earnings, WVE or ERAS? Wave Life Sciences has higher revenue and earnings than Erasca. Wave Life Sciences is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWave Life Sciences$108.30M12.77-$57.51M-$0.79-11.41ErascaN/AN/A-$125.04M-$0.74-2.09 Does the media refer more to WVE or ERAS? In the previous week, Wave Life Sciences had 5 more articles in the media than Erasca. MarketBeat recorded 23 mentions for Wave Life Sciences and 18 mentions for Erasca. Wave Life Sciences' average media sentiment score of 0.83 beat Erasca's score of 0.58 indicating that Wave Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Wave Life Sciences 11 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in WVE or ERAS? 89.7% of Wave Life Sciences shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 29.1% of Wave Life Sciences shares are held by company insiders. Comparatively, 21.5% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate WVE or ERAS? Wave Life Sciences presently has a consensus price target of $22.60, suggesting a potential upside of 150.83%. Erasca has a consensus price target of $4.83, suggesting a potential upside of 211.83%. Given Erasca's higher probable upside, analysts clearly believe Erasca is more favorable than Wave Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Erasca 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor WVE or ERAS? Wave Life Sciences received 337 more outperform votes than Erasca when rated by MarketBeat users. However, 74.36% of users gave Erasca an outperform vote while only 67.78% of users gave Wave Life Sciences an outperform vote. CompanyUnderperformOutperformWave Life SciencesOutperform Votes36667.78% Underperform Votes17432.22% ErascaOutperform Votes2974.36% Underperform Votes1025.64% Which has more risk and volatility, WVE or ERAS? Wave Life Sciences has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500. Comparatively, Erasca has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Is WVE or ERAS more profitable? Erasca has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Erasca's return on equity of -42.26% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Wave Life Sciences-66.50% -280.57% -52.90% Erasca N/A -42.26%-34.97% SummaryWave Life Sciences beats Erasca on 9 of the 17 factors compared between the two stocks. Remove Ads Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$439.06M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-1.877.2023.1619.03Price / SalesN/A226.01386.8193.17Price / CashN/A65.6738.1634.64Price / Book0.746.476.914.33Net Income-$125.04M$141.90M$3.20B$247.06M7 Day Performance1.31%-3.20%-2.30%-0.37%1 Month Performance13.14%-5.64%2.86%-3.85%1 Year Performance-24.76%-7.47%10.51%1.27% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca3.6638 of 5 stars$1.55+4.7%$4.83+211.8%-24.8%$439.06MN/A-1.87120Analyst ForecastNews CoverageWVEWave Life Sciences4.5876 of 5 stars$10.17-0.5%$22.60+122.2%+49.2%$1.56B$108.30M-9.16240Analyst ForecastNews CoverageIMCRImmunocore1.9541 of 5 stars$30.04+4.3%$65.64+118.5%-52.6%$1.50B$310.20M-31.62320High Trading VolumeANIPANI Pharmaceuticals3.9435 of 5 stars$64.35+3.0%$79.75+23.9%-1.9%$1.40B$614.38M-117.00600DYNDyne Therapeutics3.053 of 5 stars$12.31+2.2%$48.85+296.8%-58.6%$1.39BN/A-3.46100INDVIndivior3.4496 of 5 stars$9.99+3.2%$15.00+50.2%-54.2%$1.38B$1.19B-28.541,164Positive NewsAMPHAmphastar Pharmaceuticals4.4147 of 5 stars$27.69+3.9%$45.50+64.3%-34.5%$1.32B$731.97M9.231,620ARDXArdelyx4.3872 of 5 stars$5.42-0.9%$10.95+102.0%-30.6%$1.29B$333.62M-33.8890EVOEvotec1.8776 of 5 stars$3.59+2.3%$5.93+65.3%-57.5%$1.27B$777.05M0.004,200Gap DownETNB89bio2.8767 of 5 stars$8.70+2.7%$27.56+216.7%-20.8%$1.27BN/A-2.9940OCULOcular Therapeutix3.4206 of 5 stars$7.94+2.8%$16.29+105.1%-16.8%$1.26B$63.72M-6.02230 Remove Ads Related Companies and Tools Related Companies Wave Life Sciences Alternatives Immunocore Alternatives ANI Pharmaceuticals Alternatives Dyne Therapeutics Alternatives Indivior Alternatives Amphastar Pharmaceuticals Alternatives Ardelyx Alternatives Evotec Alternatives 89bio Alternatives Ocular Therapeutix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
